From Pricing To Patents: Hearing Signals A Potential New Focus
Executive Summary
Sen. Cornyn recommended the Judiciary Committee initiate an inquiry into drug patents after a back-and-forth with AbbVie CEO Gonzalez over the Humira patent estate at the drug pricing hearing.
You may also be interested in...
Congress Puts Focus Back On Drug Pricing With AbbVie Subpoena
House Oversight Committee Chair says AbbVie has failed to comply with requests for documents in committee's investigation of the drug pricing of 12 pharma companies.
Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation
A Republican congressman and witness discuss shortened IP protections while criticizing Nancy Pelosi's drug price negotiation plan.
Will Slew of Patent Bills Lower Drug Prices?
Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.